These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30238372)

  • 41. Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.
    Vaggelas A; Seimetz D
    Ther Innov Regul Sci; 2019 May; 53(3):364-373. PubMed ID: 29895180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Designing regenerative biomaterial therapies for the clinic.
    Pashuck ET; Stevens MM
    Sci Transl Med; 2012 Nov; 4(160):160sr4. PubMed ID: 23152328
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure.
    Mata-Miranda MM; Delgado-Macuil RJ; Rojas-Lopez M; Martinez-Flores R; Vazquez-Zapien GJ
    Curr Stem Cell Res Ther; 2017; 12(5):423-431. PubMed ID: 28322169
    [TBL] [Abstract][Full Text] [Related]  

  • 44. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological Products: Cellular Therapy and FDA Approved Products.
    Golchin A; Farahany TZ
    Stem Cell Rev Rep; 2019 Apr; 15(2):166-175. PubMed ID: 30623359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Regenerative Medicine Venturing at the University-Industry Boundary: Implications for Institutions, Entrepreneurs, and Industry.
    Bock AJ; Johnson D
    Adv Exp Med Biol; 2018; 1098():213-236. PubMed ID: 30238374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potency evaluation of tissue engineered and regenerative medicine products.
    Guthrie K; Bruce A; Sangha N; Rivera E; Basu J
    Trends Biotechnol; 2013 Sep; 31(9):505-14. PubMed ID: 23932143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulatory enablers and regulatory challenges for the development of tissue-engineered products in the EU.
    Brévignon-Dodin L
    Biomed Mater Eng; 2010; 20(3):121-6. PubMed ID: 20930319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Science-based assessment of source materials for cell-based medicines: report of a stakeholders workshop.
    Stacey G; Andrews P; Asante C; Barbaric I; Barry J; Bisset L; Braybrook J; Buckle R; Chandra A; Coffey P; Crouch S; Driver P; Evans A; Gardner J; Ginty P; Goldring C; Hay DC; Healy L; Hows A; Hutchinson C; Jesson H; Kalber T; Kimber S; Leathers R; Moyle S; Murray T; Neale M; Pan D; Park BK; Rebolledo RE; Rees I; Rivolta MN; Ritchie A; Roos EJ; Saeb-Parsy K; Schröder B; Sebastian S; Thomas A; Thomas RJ; Turner M; Vallier L; Vitillo L; Webster A; Williams D
    Regen Med; 2018 Dec; 13(8):935-944. PubMed ID: 30488776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Translational Cell Therapies in Regenerative Medicine and Cancers.
    Lin SZ
    Cell Transplant; 2016; 25(5):781-2. PubMed ID: 27102174
    [No Abstract]   [Full Text] [Related]  

  • 54. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 55. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
    Lysaght T; Sugii S
    Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
    [No Abstract]   [Full Text] [Related]  

  • 58. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
    Babizhayev MA; Yegorov YE
    J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Balancing tissue and tumor formation in regenerative medicine.
    Bailey AM
    Sci Transl Med; 2012 Aug; 4(147):147fs28. PubMed ID: 22896673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regenerative medicine: future impact on clinical therapies and society.
    Kargul J; Laurent GJ; Irminger-Finger I
    Int J Biochem Cell Biol; 2014 Nov; 56():1. PubMed ID: 25461768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.